Fulcrum Therapeutics

DividendsFulcrum Therapeutics

FULC

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

See below the complete and updated table with all dividends paid and declared history, etc

This company has not yet paid dividends.